Skip to main content

Accelerate Diagnostics Value Stock - Dividend - Research Selection

Accelerate diagnostics

ISIN: US00430H1023 , WKN: A1KA68

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Accelerate Diagnostics Unveils Executive Incentive Plan Linked to FDA Goals

2024-05-30
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

12 Health Care Stocks Moving In Thursday's After-Market Session

2024-05-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

12 Health Care Stocks Moving In Tuesday's Intraday Session

2024-05-21
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Accelerate Diagnostics’ Shareholder Decisions at Annual Meeting

2024-05-13
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q1 2024 Earnings Call Transcript

2024-05-09
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q1 2024 Earnings Call Transcript May 8, 2024 Accelerate Diagnostics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to the Accelerate Diagnostics Incorporated. First Quarter 2024 Results Conference Call. All participants […]

Q1 2024 Accelerate Diagnostics Inc Earnings Call

2024-05-09
Q1 2024 Accelerate Diagnostics Inc Earnings Call

Accelerate Diagnostics Inc (AXDX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...

2024-05-09
Despite a slight revenue increase and reduced operational costs, AXDX faces a growing net loss and strategic hurdles in advancing its WAVE system.

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates

2024-05-08
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -22.22% and 2.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results

2024-05-08
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial preliminary results for the first quarter ended March 31, 2024.

Accelerate Diagnostics, Inc. (AXDX) Q1 2024 Earnings Call Transcript

2024-05-08
Accelerate Diagnostics, Inc. (NASDAQ:NASDAQ:AXDX) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ETCompany ParticipantsLaura Pierson - Investor...